Moderna (MRNA) Depreciation & Amortization (CF) (2018 - 2026)

Moderna (MRNA) has 9 years of Depreciation & Amortization (CF) data on file, last reported at $59.0 million in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 51.28% year-over-year to $59.0 million in Q1 2026; TTM through Mar 2026 was $235.0 million, a 22.4% increase from a year earlier, with the FY2025 full-year figure at $215.0 million, up 13.76% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $59.0 million, down from $67.0 million in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for MRNA reached as high as $249.0 million in Q3 2023 and fell as low as $36.0 million in Q1 2024.
• Historically, Depreciation & Amortization (CF) has averaged $84.2 million across 5 years, with a median of $67.0 million in 2025.
• Across the five-year window, Depreciation & Amortization (CF) soared 426.67% in 2022 and tumbled 79.12% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $80.0 million in 2022, then surged by 152.5% to $202.0 million in 2023, then sank by 70.3% to $60.0 million in 2024, then climbed by 11.67% to $67.0 million in 2025, then slipped by 11.94% to $59.0 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $59.0 million in Q1 2026, $67.0 million in Q4 2025, and $52.0 million in Q3 2025.